ArticleEndocrine connections2026
Effects of burosumab on macrophage polarization and TRPV1 expression in children with XLH.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeX-linked hypophosphatemia (XLH) is a rare genetic disorder caused by PHEX mutations, leading to hypophosphatemia and impaired bone mineralization. Burosumab, a monoclonal antibody targeting FGF23, improves phosphate levels and bone health. Although burosumab improves musculoskeletal pain, it remains unclear whether this benefit results solely from restoration of phosphate homeostasis or also involves immunomodulatory mechanisms. Given the role of FGF23 in modulating macrophage function and the involvement of TRPV1 - expressed by macrophages - in pain transmission, we investigated the effects of burosumab on macrophage polarization and TRPV1 expression in children with XLH.
methodsMacrophages were isolated from untreated XLH patients (n = 4), burosumab-treated XLH patients (n = 8), and healthy donors (n = 5). Western blot was used to assess M1 (CCR7, CD86, iNOS) and M2 (CD206, p-STAT6) markers, as well as TRPV1 expression. To evaluate burosumab's direct effects, macrophages from healthy donors were stimulated with LPS and treated with 1.5 or 3 μg/mL burosumab, followed by the same analyses.
resultsUntreated XLH macrophages predominantly exhibited an M1 phenotype with higher TRPV1 protein levels compared with healthy controls. In contrast, macrophages from burosumab-treated patients showed a tendency to acquire an M2-like phenotype and reduced TRPV1 expression. Similar effects were observed in vitro, with LPS-stimulated healthy macrophages shifting toward the M2 phenotype and showing decreased TRPV1 after burosumab exposure.
conclusionIn untreated XLH patients, macrophages exhibit a pro-inflammatory M1 phenotype with upregulated TRPV1 expression. Burosumab reverses this profile, driving M2 polarization and reducing TRPV1 levels, thereby suggesting that it exerts therapeutic effects beyond phosphate homeostasis through immunomodulation. PLAIN SUMMARY: X-linked hypophosphatemia (XLH) causes rickets and chronic pain. We found that immune cells from untreated patients show a pro-inflammatory profile. Treatment with burosumab shifted these immune cells toward an anti-inflammatory state and reduced the expression of TRPV1, a molecule involved in neuroimmune signaling, suggesting that burosumab may exert biological effects beyond bone health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.